ReviewWorld journal of oncology2019
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.
Review in World journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,279 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence Estimation of BRCA1, BRCA2 and Other Germline Mutations Associated With Hereditary Pancreatic Cancer Using a Comprehensive Gene Panel in an Unselected Cohort of Patients With Pancreatic Adenocarcinoma in Mexico
The Outcome After Operation for Pancreatic and Periampullary Tumors in Greeland Inuit.
Indocyanine Green Fluorescence in Evaluation of Post-resection Pancreatic Remnant Perfusion After Pancreaticoduodenectomy
Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX: a Prospective, Pilot Study
HIPANC-002 - Observational Performance Study of Transcriptome-Based OncoTreat/OncoTarget Testing With Patient-Derived Organoids in Metastatic Pancreatic Cancer
Who cites it
1,279 citing papers in PubMed, 7 syntheses or guidelines pooled it, 2,245 citations in OpenAlex.
- What Are Computer-Assisted Methods Achieving in Fine-Needle Aspiration Cytology of the Pancreas? A Systematic Review and Meta-Analysis.Cytopathology : official journal of the British Society for Clinical Cytology · 2026Pooled it
- Quantifying Weight Loss Prior to Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis.Cancer medicine · 2026Pooled it
- High IntratumoralInternational journal of molecular sciences · 2026Pooled it
- Deep learning models for pancreatic cancer detection on CT: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Preclinical pancreatic cancer mouse models for treatment with small molecule inhibitors: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Diagnostic valuation of MMP family members as biomarkers for pancreatic cancer: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- An Updated Meta-analysis of Pancreatic Cancer Risk in Patients with Inflammatory Bowel Disease.Journal of gastrointestinal cancer · 2025Pooled it
- Longitudinal assessment of health-related quality of life in patients with borderline and locally advanced pancreatic cancer undergoing neoadjuvant FOLFIRINOX chemotherapy: results from a prospective multicenter trial.Langenbeck's archives of surgery · 2026Trial
- Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.Nature medicine · 2026Trial
- NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.Nature communications · 2026Trial
- Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial.Journal for immunotherapy of cancer · 2025Trial
- Nonlinear Modeling Reveals Novel Associations Between Genetically Predicted Protein Levels and Pancreatic Cancer Risk.Molecular carcinogenesis · 2026Article
- Article
- Clinical and imaging differences between pancreatic carcinoma in situ and T1a/T1b pancreatic ductal adenocarcinoma.Abdominal radiology (New York) · 2026Article
- Article
- NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study.ESMO gastrointestinal oncology · 2026Article
- Pre-operative neutrophil-to-lymphocyte ratio significantly predicts local recurrence in pancreatic ductal adenocarcinoma.Annals of hepato-biliary-pancreatic surgery · 2026Article
- Current burden, incidence trends, and future projections of pancreatic cancer in adults worldwide.Journal of global health · 2026Article
- Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectomy: a single-center retrospective study.Surgical endoscopy · 2026Article
- Article
1,219 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,242 new deaths in 2018 (GLOBOCAN 2018 estimates). Globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040. Despite advancements in the detection and management of pancreatic cancer, the 5-year survival rate still stands at 9% only. To date, the causes of pancreatic carcinoma are still insufficiently known, although certain risk factors have been identified, such as tobacco smoking, diabetes mellitus, obesity, dietary factors, alcohol abuse, age, ethnicity, family history and genetic factors,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.